Etoposide is an antineoplastic agent widely used for treatment of many pediatric cancers. Etoposide has been associated with infusion‐related reactions. In this brief report, we compare etoposide infusion‐related reactions that occurred over a 10‐year period at two freestanding pediatric hospitals. Infusion reactions occurred in 1% of patients at two hospitals across the study period. Rates of 4.8%, 3.4%, and 7.9% were observed at Children's Mercy Hospital during 2018, 2019, and 2020, respectively, after the implementation of in‐line filters during etoposide infusions in late 2017. Of the 32 patients who experienced adverse reactions, 41% were rechallenged after the reaction and all were able to tolerate at least one future dose with either pre‐treatment or extending infusion duration. This work highlights the importance of a multicenter approach to investigating adverse drug reactions (ADRs) as variation in practice can provide key information about ADRs and potential risk factors.
Etoposide is an antineoplastic agent widely used for treatment of many
pediatric cancers and associated with infusion related adverse drug
reactions (ADRs). In this brief report we describe etoposide infusion
related ADRs that occurred over a 10-year period at two freestanding
pediatric hospitals. Infusion reactions occurred in 1% of patients. Of
the 32 patients that experienced adverse reactions, 41% were
rechallenged after the reaction and all were able to tolerate at least
one future dose with either pre-treatment or extending infusion
duration.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.